Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study.

Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, Leoncini F, Scerbo A, Tundo P, Abrescia N, Moroni M; Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study Group.

J Infect Dis. 2002 Apr 15;185(8):1062-9. Epub 2002 Apr 1.

PMID:
11930316
2.

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.

Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A.

HIV Med. 2004 Mar;5(2):105-9.

3.

Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group.

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50.

PMID:
15097150
4.

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.

Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K; N2R Study Team.

Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114.

PMID:
19438397
5.

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.

Manfredi R, Calza L, Chiodo F.

J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):492-502.

PMID:
15021314
6.

The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.

Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):140-6. doi: 10.1097/QAI.0b013e3181a56e81.

PMID:
19352201
7.

A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.

Cozzi-Lepri A, De Luca A, Phillips AN, Bongiovanni M, Di Giambenedetto S, Mena M, Moioli MC, Arlotti M, Sighinolfi L, Narciso P, Lichtner M, Cauda R, Monforte Ad; ICoNA Study Group; UCSC-Roma HIV Cohort Study Group; IMIT Study Group.

J Infect Dis. 2006 Jul 1;194(1):20-8. Epub 2006 May 16.

PMID:
16741878
8.

Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.

Friedl AC, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer H, Bucher HC, Bernasconi E, Weber R; Swiss Cohort Study.

AIDS. 2001 Sep 28;15(14):1793-800.

PMID:
11579241
9.

Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.

Torti C, Maggiolo F, Patroni A, Suter F, Ladisa N, Paraninfo G, Pierotti P, Orani AM, Minoli L, Arici C, Sighinolfi L, Tinelli C, Carosi G; MASTER Cohort.

J Antimicrob Chemother. 2005 Jul;56(1):190-5. Epub 2005 May 25.

PMID:
15917286
10.

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team.

N Engl J Med. 2003 Sep 11;349(11):1036-46.

11.

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.

Allavena C, Ferré V, Brunet-François C, Delfraissy JF, Lafeuillade A, Valantin MA, Bentata M, Michelet C, Poizot-Martin I, Dailly E, Launay O, Raffi F; Bitherapy Kaletra-Sustiva Study Group.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):300-6.

PMID:
15980689
12.

Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.

Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):350-64.

PMID:
11468423
13.

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG.

AIDS. 2002 Jan 4;16(1):53-61.

PMID:
11741163
15.
16.
17.

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team.

N Engl J Med. 2001 Aug 9;345(6):398-407.

18.

Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.

Scherpbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JM, Kuijpers TW.

Pediatrics. 2007 Mar;119(3):e705-15. Epub 2007 Feb 16.

PMID:
17308244
19.

Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.

Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Clin Infect Dis. 2007 Jan 1;44(1):120-7. Epub 2006 Nov 16.

PMID:
17143827
20.

Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.

Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV.

AIDS. 2006 Oct 24;20(16):2099-106.

PMID:
17053356

Supplemental Content

Support Center